Lv2
126 积分 2023-03-22 加入
Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma
1个月前
已关闭
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
1个月前
已完结
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
1个月前
已完结
Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study
1个月前
已完结
Advances in Systemic Therapy for Lung Cancer
2个月前
已关闭
Cutting edge therapies: A review of Food and Drug Administration‐ approved drugs for non‐small cell lung cancer
2个月前
已完结
Targeting HER2 heterogeneity in breast and gastrointestinal cancers
2个月前
已完结
Reduced-Dose Enfortumab Vedotin, Treatment Continuity, and Survival in Urothelial Cancer
2个月前
已完结
Dynamics of Tumor-informed Circulating Tumor DNA and Association with Clinical Responses to Enfortumab and Pembrolizumab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
4个月前
已完结
Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma
4个月前
已完结
皖公网安备34019202002308
